Akebia Reports Q2 Vafseo Revenue Growth, Sets Sights on Expanding Access to 275,000 Dialysis Patients

Akebia Therapeutics generated $13 million in Vafseo revenue in Q2, a 55% increase from Q1. CEO John P. Butler reported access to over 275,000 dialysis patients for Vafseo in Q4, with a DaVita pilot launch underway.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) has reported robust financial results for the second quarter of 2025, with revenue smashing expectations and significant growth in its Vafseo product. The company's CEO, John P. Butler, highlighted the strong momentum of Vafseo, which generated $13.3 million in net product revenues, a 55% increase from the first quarter of 2025 [2]. This growth was driven by a substantial increase in prescription demand, with more than 725 prescribers writing over 13 prescriptions on average during the quarter.

The company's total revenues for the second quarter of 2025 reached $62.5 million, up from $43.6 million in the same period last year. This was primarily due to the launch of Vafseo in the U.S. in January 2025 and an increase in Auryxia sales. Auryxia, another key product, generated $47.2 million in net product revenues, compared to $41.2 million in the second quarter of 2024 [2].

Butler also announced that DaVita, a leading dialysis organization, has begun an operational pilot to prescribe Vafseo to patients. This pilot is expected to expand access to over 100 clinics, potentially reaching more than 75,000 patients by the end of the third quarter [2]. Additionally, the company is working towards operationalizing protocols with other dialysis organizations, including Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC), to further increase Vafseo's availability.

The company's net income for the second quarter of 2025 was $0.2 million, compared to a net loss of $8.6 million in the same period last year. This improvement was driven by the increase in net product revenues, partially offset by non-cash expenses related to the change in fair value of warrant liability and interest expense related to the Vifor Termination and Settlement Agreement [2].

Akebia Therapeutics is well-positioned to continue its growth trajectory, with a strong cash position of approximately $137.3 million as of June 30, 2025. The company believes it is financed to achieve profitability based on its current operating plan, which includes pursuing label expansion for Vafseo and advancing other existing programs [2].

References:
[1] https://www.marketscreener.com/news/akebia-therapeutics-q2-revenue-smashes-expectations-ce7c5edfdd89fe23
[2] https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-second-quarter-2025-financial